A practical reference on hGH fragment: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-06-12 and is reviewed periodically as new material appears.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Peptide fragment | Corresponds to hGH residues 176-191 |
| Common synonyms | AOD9604, hGH 176-191 | Also written as AOD-9604 |
| Typical form | Lyophilized powder | Often supplied in sealed vials |
| Solubility | Water-soluble | Dissolves in aqueous buffers |
| Regulatory status | Not approved as drug | Banned in sport; varies by country |
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
That promise is null and void if Zverev – and the media – isn't willing to be honest." At the beginning of the 2024 Australian Open, a court official announced that Zverev was scheduled to stand trial before the Tiergarten District Court in Berlin. The timing of the announcement, combined with Zverev's semifinal run at the tournament, brought heightened interest in and scrutiny of the allegations from both the press and the public. The trial began on 31 May 2024. On 7 June 2024, the third day of the trial, the judge agreed to a request by the public prosecution office, endorsed by the alleged victim, to provisionally terminate the proceedings subject to the condition that Zverev pay €200,000, of which €150,000 would go to the German State Treasury and €50,000 to charitable organizations. The trial therefore concluded without a finding of guilt. The prosecutor's request to terminate the proceedings followed an out-of-court agreement between Zverev and the alleged victim, the terms of which were not disclosed. According to his counsel, Zverev entered into the agreement "to put a quick end to the proceedings – above all in the interest of their child", emphasizing that the agreement "includes no determination or admission of guilt".
Norhydrocodone is the major metabolite of the opioid analgesic hydrocodone. It is formed from hydrocodone in the liver via N-demethylation predominantly by CYP3A4. Unlike hydromorphone, a minor metabolite of hydrocodone, norhydrocodone is described as inactive. However, norhydrocodone is actually an agonist of the μ-opioid receptor with similar potency to hydrocodone, but has been found to produce only minimal analgesia when administered peripherally to animals. This is likely due to poor blood-brain-barrier and thus central nervous system penetration.
Indigenous allies were crucial to conquest, as well as to creating and maintaining empire. Indigenous peoples in Colombia experienced a decline in population due to conquest as well as Eurasian diseases, such as smallpox, to which they had no immunity. Regarding the land as deserted, the Spanish Crown sold properties to all persons interested in colonized territories, creating large farms and possession of mines. In the 16th century, the nautical science in Spain reached a great development thanks to numerous scientific figures of the Casa de Contratación and nautical science was an essential pillar of the Iberian expansion. In 1542, the region of New Granada, along with all other Spanish possessions in South America, became part of the Viceroyalty of Peru, with its capital in Lima. In 1547, New Granada became a separate captaincy-general within the viceroyalty, with its capital at Santa Fe de Bogota. In 1549, the Royal Audiencia was created by a royal decree, and New Granada was ruled by the Royal Audience of Santa Fe de Bogotá, which at that time comprised the provinces of Santa Marta, Rio de San Juan, Popayán, Guayana and Cartagena. But important decisions were taken from the colony to Spain by the Council of the Indies.
==== Surfactins ==== As the name implies, surfactins are potent biosurfactants (surfactants produced by bacteria, yeast, or fungi), and they have been shown to reduce the surface tension of water from 72 to 27 mN/m at very low concentrations. Furthermore, surfactins are also able to permeabilize lipid membranes, allowing them to have specific antimicrobial and antiviral activities. Since surfactins are biosurfactants, they have diverse functional properties. These include low toxicity, biodegradability and a higher tolerance towards variation of temperature and pH, making them very interesting for use in a wide range of applications.
Though the band's previous taste for improvisation was now tightly reined in, one instrumental ("The Sheltering Sky") emerged from group rehearsals, while the noisy, half-spoken/half-shouted "Indiscipline" was a part-written, part-improvised piece created in order to give Bruford a chance to escape from the strict rhythmic demands of the rest of the album. Released in September 1981, Discipline reached No. 41 in the UK and No. 45 in the US. In June 1982, King Crimson followed Discipline with Beat, the first King Crimson album recorded with the same line-up as the album preceding it. Beat was also the group's only album where Fripp had no involvement in the original mixing, with Davies and Belew undertaking production duties. The album was themed around the lives and works of Beat Generation writers, reflected in song titles such as "Neal and Jack and Me" (inspired by Neal Cassady and Jack Kerouac), "Heartbeat" (inspired by Carolyn Cassady's memoir Heart Beat: My Life with Jack and Neal), "The Howler" (inspired by Allen Ginsberg's "Howl") and "Waiting Man" (inspired by William S. Burroughs). The album contained themes of life on the road, existential angst and romanticism. While Beat was more pop-influenced than Discipline, it also featured the improvised "Requiem", which featured Frippertronics, a guitar technique invented by Eno and Fripp using a tape loop system. The recording of Beat was marred by tension within the band, with Belew suffering stress over his duties as frontman, lead singer, and principal songwriter.
Sources: en.wikipedia.org
Tea was consumed as a recreational and social beverage during the Tang dynasty, and Chinese tea culture-inspired ceremonial drinking spread to other Sinospheric countries such as Japan (where it is known as chado), Korea (known as darye) and Vietnam (typically as part of a wedding ritual). Tea drinking also spread into Inner Asia and South Asia via the Silk Road and the Tea Horse Road, particularly during the expansion of the Mongols, for whom the salted milk tea (süütei tsai) has remained part of the staple diet. Outside of the Far East, Portuguese priests and merchants introduced tea drinking to Europe during the 16th century. During the 17th century, drinking tea became fashionable in Western Europe as part of the rise of Chinoiserie influence, especially among the British, who had such a high import demand of tea that they later started to cultivate tea on a large scale in colonial India and Ceylon, where tea had previously been used only as a herbal medicine.
== Research career == After obtaining his Ph.D., his first job was in research for Parke, Davis and Company, and his first task was to isolate the hormone associated with the thyroid gland. He continued this research at St. Luke's Hospital in New York until 1914. He was appointed Head of the Biochemistry Section in the Graduate School of the Mayo Foundation, and the following year he was appointed as the Director of the Division of Biochemistry. Kendall made several significant contributions to biochemistry and medicine. His most important discovery was the isolation of thyroxine, although it was not the work for which he received the most accolades. Along with associates, Kendall was involved with the isolation of glutathione and determining its structure. He also isolated several steroids from the adrenal gland cortex, one of which was initially called Compound E. Working with Mayo Clinic physician Philip Showalter Hench, Compound E was used to treat rheumatoid arthritis. The compound was eventually named cortisone. In 1950, Kendall and Hench, along with Swiss chemist Tadeus Reichstein were awarded the 1950 Nobel Prize in Physiology or Medicine for "their discoveries relating to the hormones of the adrenal cortex, their structure and biological effects." His Nobel lecture focused on the basic research that led to his award, and was titled "The Development of Cortisone As a Therapeutic Agent." As of the 2010 awards, Kendall and Hench were the only Nobel Laureates to be affiliated with Mayo Clinic.
Mescaline - Isomer Design Mescaline - PsychonautWiki Mescaline - Erowid Mescaline - PiHKAL - Erowid Mescaline - PiHKAL - Isomer Design Mescaline - The Shulgin Index Mescaline - Trout's Notes Archive List for The Big and Dandy Basic Mescaline/Cactus Threads - Bluelight The Mescaline Experiment: Humphry Osmond and Christopher Mayhew - YouTube
Ceramic petrography (or ceramic petrology) is a laboratory-based scientific archaeological technique that examines the mineralogical and microstructural composition of ceramics and other inorganic materials under the polarised light microscope in order to interpret aspects of the provenance and technology of artefacts. The process of ceramic petrography involves careful sample preparation. Small sections of the ceramic material are carefully ground down to a thickness of approximately 0.03 mm and then mounted on glass slides. These thin sections allow for the examination of the internal structure of the ceramics and facilitate the identification of mineral phases, crystalline structures, and textural features. The methodology of ceramic petrography draws upon principles from various fields, including optical mineralogy, thin section petrography, and soil micromorphology
Because dextromethorphan (DXM) acts predominantly as the parent compound rather than through dextrorphan in Auvelity, the contribution of the active metabolite can largely be disregarded when analyzing Auvelity's pharmacological effects. Dextrorphan primarily provides NMDA channel blockade. However, DXM itself exhibits its strongest activity as a serotonin transporter (SERT) inhibitor and σ1 receptor agonist, while its NMDA antagonism is actually quite weak. In Auvelity, the conversion of DXM to dextrorphan by the CYP2D6 enzyme is substantially inhibited by bupropion, resulting in extremely high plasma concentrations of the parent DXM. Consequently, Auvelity's NMDA receptor antagonism is clinically quite limited, whereas σ1 receptor agonism and SERT inhibition become the dominant pharmacological actions. Based on pharmacokinetic data, it can be inferred that DXM in Auvelity may achieve approximately 60–85% whole-brain SERT occupancy, a level comparable to that of most SSRIs (selective serotonin reuptake inhibitors). In addition, σ1 receptor agonism, which was previously investigated as a target for antidepressant development, likely contributes to Auvelity's therapeutic efficacy. Bupropion produces relatively strong inhibition of the norepinephrine transporter (NET) and achieves approximately 14–28% dopamine transporter (DAT) occupancy, making it an NDRI (norepinephrine-dopamine reuptake inhibitor). Bupropion also antagonizes nicotinic acetylcholine receptors, acts as a weak positive allosteric modulator of the σ1 receptor, and inhibits 5-HT3 receptors.
Sources: en.wikipedia.org
AOD-9604 is a synthetic peptide fragment of human growth hormone, corresponding to amino acids 176-191. It is studied for potential effects on fat metabolism, but it is not approved as a drug in most countries. Its exact mechanism remains under investigation.
No, it is a small fragment of the full growth hormone protein. It does not appear to stimulate growth or increase growth hormone levels in the same way. Its actions are thought to be more limited to metabolic pathways.
Regulatory status varies. It is not approved for medical use in the United States or many other countries. It is banned in sport by WADA, and its sale as a supplement or research chemical may be subject to legal restrictions.
AOD9604 is a synthetic peptide based on a C-terminal segment of human growth hormone. It is manufactured by chemical peptide synthesis rather than extracted from human tissue. The sequence is often described as hGH fragment 176–191 or a close variant.